CABALETTA BIO, INC. Share-based Payment Arrangement, Expense
CABALETTA BIO, INC. (CABA) reported Share-based Payment Arrangement, Expense of $3.02 thousand for the 6-month period ending 2025-06-30, per its 10-K filed 2026-03-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-13
- CABALETTA BIO, INC. share-based payment arrangement, expense for fiscal 2019 was $2.30M, a 279.54% increase from fiscal 2018.
- CABALETTA BIO, INC. share-based payment arrangement, expense for fiscal 2018 was $606.00K.
| Period end | Share-based Payment Arrangement, Expense | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2025-06-30 | $3.02K 10-K · filed 2026-03-23 | $3.02M 10-Q · filed 2025-08-07 | ||
| 2025-05-19 | $3.02M 10-Q · filed 2026-08-13 | |||
| 2019-12-31 | $2.30M 10-K · filed 2020-03-30 | |||
| 2018-12-31 | $606.00K 10-K · filed 2020-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |